Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals Inc (NQ: VRPX )

0.4277 -0.1393 (-24.57%)
Streaming Delayed Price Updated: 9:43 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Virpax Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
From Virpax Pharmaceuticals
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on! 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces CFO Transition
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Reports on Progress of Envelta™
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals 2022 R&D Expenses Grow 122% To $10.8M, Here Are The Details
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) released its financial results for the twelve months ended December 31, 2022, and other recent developments. FY 2022 Financial Highlights 
Via Benzinga
Virpax Pharmaceuticals Reports 2022 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Virpax Completes FDA Required Preclinical Toxicology Studies For Its Licensed Molecular Envelope Technology
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX), has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET). MET enhances the delivery of Virpax’s... 
Via Benzinga
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
From Virpax Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Engages Physicians Experienced In Childhood Epilepsy To Assist In Development Of NobrXiol
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) has engaged two physicians experienced in childhood epilepsy, Dr. Kenneth W. Sommerville and Dr. Lawrence Fried, to support the overall development plan for... 
Via Benzinga
Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 75 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Virpax Receives pre-IND Application Guidance From The FDA For Its CBD-Based Drug Candidate For Epilepsy
Virpax Pharmaceuticals, Inc. 
Via Benzinga
Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  OnThursday, 137 stocks made new 52-week lows. 
Via Benzinga
Virpax Pharmaceuticals Reports 2022 Third Quarter Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.